Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma

Nanomedicine, Journal Year: 2025, Volume and Issue: 20(3), P. 255 - 270

Published: Jan. 15, 2025

Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting agent, such as the humanized anti-GPC3 antibody GC33 (condrituzumab), attached surface. Here, we investigated use of idarubicin-loaded CS-NBs for HCC treatment GC33-derived minibody (that named 4A1) CS-NB delivery. Various formulations were prepared with or without 4A1 conjugation idarubicin loading. had positive charge diameter about 360 nm. In in-vitro experiments HCC-like HUH7 cell line, showed cytotoxic effect once loaded idarubicin. In-vivo biodistribution tumor-bearing xenograft mice demonstrated that can accumulate tumor mass. This was enhanced by (p = 0.0317). mice, conjugated not both able slow growth, increase mouse survival time compared free 0.00044 0.0018, respectively) well effects. useful strategy

Language: Английский

What are the future applications of chitosan nanobubbles in drug delivery?

Expert Opinion on Drug Delivery, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 4, 2025

Language: Английский

A review on polysaccharide-based tumor targeted drug nanodelivery systems

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 140820 - 140820

Published: Feb. 1, 2025

Language: Английский